Analyst Price Target is $57.86
▲ +80.80% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $57.86, with a high forecast of $85.00 and a low forecast of $26.00. The average price target represents a 80.80% upside from the last price of $32.00.
Current Consensus is
Buy
The current consensus among 14 polled investment analysts is to buy stock in Kymera Therapeutics.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More